



Dkt. 41426-F-PCT-A-US/JPW/MAF/AJD

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ron S. Israeli et al.
U.S. Serial No.: 10/751,346
Filed: January 2, 2004
For: PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES
THEREOF

1185 Avenue of the Americas
New York, New York 10036
March 26, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This Supplemental Information Disclosure Statement is submitted under 37 C.F.R. §1.97(b)(3) to supplement the Information Disclosure Statements filed on January 2, 2004 in connection with the above-identified application.

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following references which are listed on the attached PTO-1449 form (**Exhibit A**), and attached hereto as **Exhibits 1-58**:

1. U.S. Patent No. 4,554,101, issued November 19, 1985 to Thomas P. Hopp;
2. U.S. Patent No. 5,162,504, issued November 10, 1992 to Julius S. Horoszewicz;
3. U.S. Patent No. 5,538,866, issued July 23, 1996 to Israeli et al.;
4. PCT International Application No. PCT/US93/10624, filed November 5, 1993, International Publication No. WO 94/09820, published May 11, 1994;
5. Abdel-Nabi, H., Wright, G.L., Gulfo, J.V., Petrylak, D.P., Neal, C.E. et al. (1992) Monoclonal Antibodies and

- Radioimmunoconjugates in the Diagnosis and Treatment of Prostate Cancer, *Semin. Urol.* 10: 45-54;
6. Axelrod, H.R. et al. (1992) Preclinical results and human immunohistochemical studies with ⁹⁰Y-CYT-356. A new prostate cancer therapeutic agent, *Abstract 596. AUA 87th Annual Meeting*, May 10-14, 1992, Washington, D.C.;
 7. Carter, B.H. and Coffey, D.S. (1990) The Prostate: An Increasing Medical Problem, *The Prostate* 16: 39-48;
 8. Chang, C.S., Kokontis, J. and Liao, S.T. (1988) Structural Analysis of Complementary DNA and Amino Acid Sequences of Human and Rat Androgen Receptors, *Proc. Natl. Acad. Sci. USA* 85: 7211-7215;
 9. Corr, J.G. et al. (1994) Prostate Specific Membrane Antigen (PSM) Expression in Orthotopically Implanted Human Prostate Cancer Cells in Nude Mice Slows Tumor Growth and Metastatic Potential, *J. Urol.* 151: 492A;
 10. Culver, K.W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E.H. and Blaese, R.M. (1992) In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors, *Science* 256: 1150-1152;
 11. Decensi, A., Guarneri, D., Paoletti, M.C., Lalanne, J.M., Merlo, F. and Boccardo, F. (1991) Phase II Study of the Pure Non-steroidal Antiandrogen Nilutamide in Prostatic Cancer, *Eur. J. Cancer* 27: 1100-1104;
 12. Faber, P.W., van Rooij, H.C., van der Korput, H.A., Baarends, W.M., Brinkmann, A.O., Grootegeod, J.A. and Trapman, J. (1991) Characterization of the Human Androgen Transcription Unit, *J. Biol. Chem.* 266: 10743-10749;
 13. Feng, Q. et al. (1991) Purification and Biochemical Characterization of the 7E11-C5 Prostate Carcinoma-Associated Antigen, *Proc. Am. Assoc. Cancer Res.* 32: 239;
 14. Fey, M.F., Kulozik, A.E., Hansen-Hagge, T.E. and Tobler, A. (1991) The Polymerase Chain Reaction: A New Tool for the Detection of Minimal Residual Disease in Haematological

- Malignancies, *Eur. J. Cancer* 27: 89-94;
15. Henttu, P. and Vihko, P. (1989) cDNA Coding for the Entire Human Prostate Specific Antigen Shows High Homologies to the Human Tissue Kallikrein Genes, *Biochem. Biophys. Res. Commun.* 160: 903-910;
 16. Horoszewicz, J.S., Kawinski, E. and Murphy, G.P. (1987) Monoclonal Antibodies to a New Antigen Marker in Epithelial Prostatic Cells and Serum of Prostatic Cancer Patients, *AntiCancer Res.* 7: 927-936;
 17. Huber, B.E., Richards, C.A. and Krenitsky, T.A. (1991) Retroviral-mediated Gene Therapy for the Treatment of Hepatocellular Carcinoma: An Innovative Approach for Cancer Therapy, *Proc. Natl. Acad. Sci. USA* 88:8039-8043;
 18. Israeli, R.S. et al., (1992) Purification and Molecular Cloning of a New Prostate-Specific Antigen, *Cancer Res.* 52: 356;
 19. Israeli, R.S., Powell, C.T., Fair, W.R. and Heston, W.D. (1993) Molecular Cloning of a Complementary DNA Encoding a Prostate-specific Membrane Antigen, *Cancer Res.* 53: 227-230;
 20. Israeli, R.S. et al. (1993) Molecular Cloning and Characterization of a Prostate-Specific Membrane Antigen, *J. Urol.* 149: 471A;
 21. Israeli, R.S. et al. (1993) Characterization of the Prostate-Specific Membrane Antigen (PSM), *Proc. Am. Assoc. Cancer Res.* 34: 255;
 22. Israeli, R.S., Powell, C.T., Corr, J.G., Fair, W.R. and Heston, W.D. (1994) Expression of the Prostate Specific Membrane Antigen, *Cancer Res.* 54: 1807-1811;
 23. Israeli, R.S., Miller, W.H. Jr., Su, S.L., Powell, C.T., Fair, W.R. et al. (1994) Sensitive Nested Reverse Transcription Polymerase Chain Reaction Detection of Circulating Prostatic Tumor Cells: Comparison of Prostate-specific Membrane Antigen and Prostate-specific Antigen-

- based Assays, *Cancer Research* 54: 6306-6310;
24. Israeli, R.S. et al. (1994) Localization of the Prostate Specific Membrane Antigen (PSM) to the Putative Metastasis-Suppressor Region on Human Chromosome 11, *J. Urol.* 151: 252A;
 25. Israeli, R.S. et al., (1994) Sensitive Detection of Prostatic Hematogenous Micro-Metastases Using Prostate Specific Antigen (PSA) And Prostate Specific Membrane Antigen (PSM) Derived Primers in the Polymerase Chain Reaction (PCR), *J. Urol.* 151: 373A;
 26. Israeli, R.S. et al. (1994) Localization of the Prostate Specific Membrane Antigen (PSM) to the Putative Metastasis-Suppressor Region on Human Chromosome 11, *Proc. Am. Assoc. Cancer Res.* 35: 271;
 27. Keer, H.N., Kozlowski, J.M., Tsai, Y.C., Lee, C., McEwan, R.N. and Grayhack, J.T. (1990) Elevated Transferrin Receptor Content in Human Prostate Cancer Cell Lines Assessed In Vitro and In Vivo, *J. Urol.* 143: 381-385;
 28. Lopes, A. D. et al. (1993) Immunohistochemical and Pharmacokinetic Characterization of the Site-specific Immunoconjugate CYT-356 Derived from Antiprostata Monoclonal Antibody, *Cancer Res.* 50: 6423-6429;
 29. Lubahn, D.B., Brown, T.R., Simental, J.A., Higgs, H.N., Migeon, C.J., Wilson, E.M. and French, F.S. (1989) Sequence of the Intron/exon Junctions of the Coding Region of the Human Androgen Receptor Gene and Identification of a Point Mutation in a family with Complete Androgen Insensitivity, *Proc. Natl. Acad. Sci. USA* 86: 9534-9538;
 30. Lundwall, A, and Lilja, H. (1987) Molecular Cloning of Human Prostate Specific Antigen cDNA, *FEBS Lettr.* 214: 317-322;
 31. Mukhopadhyay, T., Tainsky, M., Cavender, A.C. and Roth, J.A. (1991) Specific Inhibition of K-ras Expression and Tumorigenicity of Lung Cancer Cells by Antisense RNA¹,

- Cancer Res.* 51: 1744-1748;
32. Riegman, P.H.J. et al. (1989) The Prostate-Specific Antigen Gene and the Human Glandular Kallikrein-1 Gene are Tandemly Located on Chromosome 19, *FEBS Lettr.* 247: 123-126;
 33. Sharief, F.S., Lee, H., Leuderman, M.M., Lundwall, A., Deaven, L.L., Lee, C.L. and Li, S.S. (1989) Human prostatic acid phosphatase: cDNA cloning, gene mapping and protein sequence homology with lysosomal acid phosphatase. *Biochem. Biophys. Res. Commun.* 160: 79-86;
 34. Solin, T., Kontturi, M., Pohlmann, R. and Vihko, P. (1990) Gene Expression and Prostate Specificity of Human Prostatic Acid Phosphatase (PAP): Evaluation By RNA Blot Analyses, *Biochem. Biophys. Acta* 1048: 72-77;
 35. Su, S.L., et al. (1994) Sensitive Detection of Prostatic Hematogenous Micrometastases Using Prostate Specific Antigen (PSA) and Prostate Specific Membrane Antigen (PSM) Derived Parameters in the Polymerase Chain Reaction, *Proc. Am. Assoc. Cancer Res.* 35: 271;
 36. Troyer, John K. (1994) Biochemical Characterization and Mapping of the 7E11-C5.3 Epitope of the Prostate Specific Membrane Antigen (PSMA), *Basic and Clinical Aspects of Prostate Cancer: Abstract C38*;
 37. Vihko, P., Virkkunen, P., Henttu, P., Roiko, K., Solin, T. and Huhtala, M.L. (1988) Molecular Cloning and Sequence Analysis of cDNA Encoding Human Prostatic Acid Phosphatase, *FEBS Lettr.* 236: 275-281;
 38. Vile, R.G. and Hart, I.R. (1993) In Vitro and In Vivo Targeting of Gene Expression to Melanoma Cells, *Cancer Res.* 53: 962-967;
 39. Waibel, R. et al. (1990) Therapy of Small Cell Lung Cancer Xenografts in a Nude Mouse model: Evaluation of Radioimmunotherapy and Immunotoxin Therapy, *Antibody Immunoconjugates and Radiopharmaceuticals* 34: 54;
 40. Watt, K.W.K. et al. (1986) Human Prostate-Specific Antigen:

- Structural and Functional Similarity with Serine Proteases,
Proc. Natl. Acad. Sci. USA 83: 3166-3170;
41. Wright, Jr., G.L, Feng, Q., Beckett, M.L., Lopes, D. and Gilman, S.C. (1990) Characterization of a new prostate carcinoma-associated marker: 7E11-C5. *Antibody, Immunoconjugates and Radiopharmaceuticals* 3: 89 (Abstract 193);
 42. Young, R.A. and Davis, R.W. (1983) Efficient Isolation of Genes by Using Antibody Probes, *Proc. Natl. Acad. Sci. USA* 80: 1194-1198;
 43. U.S. Patent No. 5,153,118, issued October 6, 1992 to George L. Wright, Jr. and James J. Starling;
 44. U.S. Patent No. 5,852,167, issued December 22, 1998 to Brian K. Kay and Nils B. Adey;
 45. U.S. Patent No. 5,939,258, issued August 17, 1999 to Carlo Croce et al.;
 46. U.S. Patent No. 6,107,090, issued to Neil H. Bander on August 22, 2000;
 47. U.S. Patent No. 6,136,311, issued October 24, 2000 to Neil H. Bander;
 48. U.S. Patent No. 6,150,508, issued November 21, 2000 to Murphy et al.;
 49. PCT International Application No. PCT/US97/05214, filed March 25, 1997, International Publication No. WO 97/35616, published October 2, 1997;
 50. PCT International Application No. PCT/US99/05864, filed March 18, 1999, International Publication No. WO 99/47554, published September 23, 1999;
 51. EPO International Publication No. EP 0 173 951, published December 3, 1986;
 52. Translation of the Abstract of EP 0 173 951, i.e., Reference 50;
 53. Gately, M.K., Wolitzky, A.G., Quinn, P.M. and Chizzonite, R. (1992) "Regulation of Human Cytolytic Lymphocyte

- Responses by Interleukin-12", *Cell. Immunol.* 143: 127-142;
54. Paul, W.E. (1989) *Fundamental Immunology*, Raven Press, pp. 628-629, 647-651;
 55. Rose, N.R. et al. (1986) *Manual of Clinical Laboratory Immunology*, American Society for Microbiology, 89-109;
 56. Rossi, M. C. and Zetter, B.R. (1992) Selective Stimulation of Prostatic Carcinoma Cell Proliferation by Transferrin, *Proc. Natl. Acad. Sci. USA* 89: 6197-6201;
 57. Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory Press, 16.1-16.81;
 58. Schneider, C., Owen, M.J., Banville, D. and Williams, J.G. (1984) Primary Structure of Human Transferrin Receptor Deduced from the mRNA sequence, *Nature* 311: 675-678;
 59. Stites, D.P. et al. (1991) *Basic and Clinical Immunology*, Appleton & Lange, 229-251;
 60. Su, S.L., Huang, I.P., Fair, W.R., Powell, C.T. and Heston, W.D. (1995) *Cancer Res.*, 55: 1441-1443;
 61. Tortora, G.J. et al. (1989) *Microbiology, An Introduction*, Benjamin/Cummings Publishing Co., 423-426, 471;
 62. Bowie, J.U., Reidhaar-Olson, J.F., Lim, W.A. and Sauer, R.T. (1990) Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions, *Science* 147: 1306-1310;
 63. Kumar, V., Urban, J.L., Horvath, S.J. and Hood, L. (1990) Amino Acid Variations at a Single Residue in an Autoimmune Peptide Profoundly Affect Its Properties: T-Cell Activation, Major Histocompatibility Complex Binding, and Ability to Block Experimental Allergic Encephalomyelitis, *Proc. Natl. Acad. Sci. USA* 87: 1337-1341;
 64. Lazar, E., Watanabe, S., Dalton, S. and Sporn, M.B. (1988) Transforming Growth Factor α : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities, *Mol. Cell Biol.* 8: 1247-1252;

Applicants: Ron S. Israeli et al.
U.S. Serial No.: 10/751,346
Filed: January 2, 2004
Page 8

65. U.S. Patent No. 5,672,592, issued September 30, 1997 to Paul F. Jackson and Barbara S. Slusher (**Exhibit 1**);
66. U.S. Patent No. 5,795,877, issued August 18, 1998 to Paul F. Jackson et al. (**Exhibit 2**);
67. U.S. Patent No. 5,804,602, issued September 8, 1998 to Barbara S. Slusher et al. (**Exhibit 3**);
68. U.S. Patent No. 5,863,536, issued January 26, 1999 to Paul F. Jackson et al. (**Exhibit 4**);
69. U.S. Patent No. 5,880,112, issued March 9, 1999 to Paul F. Jackson et al. (**Exhibit 5**);
70. U.S. Patent No. 5,902,817, issued May 11, 1999 to Paul F. Jackson et al. (**Exhibit 6**);
71. U.S. Patent No. 5,962,521, issued October 5, 1999 to Paul F. Jackson et al. (**Exhibit 7**);
72. U.S. Patent No. 5,968,915, issued October 19, 1999 to Paul F. Jackson et al. (**Exhibit 8**);
73. U.S. Patent No. 5,981,209, issued November 9, 1999 to Barbara S. Slusher et al. (**Exhibit 9**);
74. U.S. Patent No. 6,011,021, issued January 4, 2000 to Barbara S. Slusher et al. (**Exhibit 10**);
75. U.S. Patent No. 6,017,903, issued January 25, 2000 to Barbara S. Slusher et al. (**Exhibit 11**);
76. U.S. Patent No. 6,025,344, issued February 15, 2000 to Paul F. Jackson et al. (**Exhibit 12**);
77. U.S. Patent No. 6,025,345, issued February 15, 2000 to Paul F. Jackson et al. (**Exhibit 13**);
78. U.S. Patent No. 6,046,180, issued April 4, 2000 to Paul F. Jackson et al. (**Exhibit 14**);
79. U.S. Patent No. 6,054,444, issued April 25, 2000 to Paul F. Jackson et al. (**Exhibit 15**);
80. U.S. Patent No. 6,121,252, issued September 19, 2000 to Paul F. Jackson et al. (**Exhibit 16**);
81. U.S. Patent No. 6,271,245, issued August 7, 2001 to Paul F.

- Jackson et al. (**Exhibit 17**);
82. U.S. Patent No. 6,288,046, issued September 11, 2001 to Paul F. Jackson et al. (**Exhibit 18**);
 83. U.S. Patent No. 6,348,464, issued February 19, 2002 to Paul F. Jackson et al. (**Exhibit 19**);
 84. U.S. Patent No. 6,372,726, issued April 16, 2002 to Barbara S. Slusher et al. (**Exhibit 20**);
 85. U.S. Patent No. 6,384,022, issued May 7, 2002 to Paul F. Jackson and Barbara S. Slusher (**Exhibit 21**);
 86. U.S. Patent No. 6,395,718, issued May 28, 2002 to Barbara S. Slusher and Rena Lapidus (**Exhibit 22**);
 87. U.S. Patent No. 6,413,948, issued July 2, 2002 to Barbara S. Slusher et al. (**Exhibit 23**);
 88. U.S. Patent No. 6,452,044, issued September 17, 2002 to Paul F. Jackson et al. (**Exhibit 24**);
 89. U.S. Patent No. 6,458,775, issued October 1, 2002 to Paul F. Jackson et al. (**Exhibit 25**);
 90. U.S. Patent No. 6,479,471, issued November 12, 2002 to Paul F. Jackson et al. (**Exhibit 26**);
 91. U.S. Patent No. 6,586,623, issued July 1, 2003 to Takashi Tsukamoto et al. (**Exhibit 27**);
 92. Barbara S. Slusher and Krystyna Wozniak, U.S. Serial No. 09/866,729, filed May 30, 2001, U.S. Publication No. 20020013295, published January 31, 2002 (**Exhibit 28**);
 93. Paul F. Jackson et al., U.S. Serial No. 09/866,758, filed May 30, 2001, U.S. Publication No. 20020019430, published February 14, 2002 (**Exhibit 29**);
 94. Paul F. Jackson et al., U.S. Serial No. 09/880,861, filed June 15, 2001, U.S. Publication No. 20010044459, published November 22, 2001 (**Exhibit 30**);
 95. Takashi Tsukamoto et al., U.S. Serial No. 10/046,917, filed January 17, 2002, U.S. Publication No. 20030105088, published June 5, 2003 (**Exhibit 31**);

Applicants: Ron S. Israeli et al.
U.S. Serial No.: 10/751,346
Filed: January 2, 2004
Page 10

96. Barbara S. Slusher et al., U.S. Serial No. 10/056,079, filed January 28, 2002, U.S. Publication No. 20020151503, published October 17, 2002 (**Exhibit 32**);
97. Barbara S. Slusher et al., U.S. Serial No. 10/119,828, filed April 11, 2002, U.S. Publication No. 20030064912, published April 13, 2003 (**Exhibit 33**);
98. Paul F. Jackson et al., U.S. Serial No. 10/164,553, filed June 10, 2002, U.S. Publication No. 20030083374, published May 1, 2003 (**Exhibit 34**);
99. Barbara S. Slusher et al., U.S. Serial No. 10/209,011, filed August 1, 2002, U.S. Publication No. 20030017965, published January 23, 2003 (**Exhibit 35**);
100. Takashi Tsukamoto et al., U.S. Serial No. 10/431,462, filed May 8, 2003, U.S. Publication No. 20030216468, published November 20, 2003 (**Exhibit 36**);
101. U.S. Patent No. 5,773,292, issued June 30, 1998 to Neil H. Bander (**Exhibit 37**);
102. U.S. Patent No. 6,649,163, issued November 18, 2003 to Neil H. Bander (**Exhibit 38**);
103. Neil H. Bander, U.S. Serial No. 09/929,543, filed August 13, 2001, U.S. Publication No. 20020015704, published February 7, 2002 (**Exhibit 39**);
104. Neil H. Bander, U.S. Serial No. 09/929,546, filed August 13, 2001, U.S. Publication No. 20030031673, published February 13, 2003 (**Exhibit 40**);
105. David M. Nanus et al., U.S. Serial No. 10/160,994, filed May 30, 2002, U.S. Publication No. 20030007974, published January 9, 2003 (**Exhibit 41**);
106. Neil H. Bander, U.S. Serial No. 09/357,704, filed July 20, 1999;
107. Neil H. Bander, U.S. Serial No. 09/357,707, filed July 20, 1999;
108. Neil H. Bander, U.S. Serial No. 09/357,708, filed July 20, 1999;

Applicants: Ron S. Israeli et al.
U.S. Serial No.: 10/751,346
Filed: January 2, 2004
Page 11

109. Neil H. Bander, U.S. Serial No. 09/357,709, filed July 20, 1999;
110. Neil H. Bander, U.S. Serial No. 09/357,710, filed July 20, 1999;
111. Gerald P. Murphy et al., U.S. Serial No. 09/561,462, filed April 28, 2000;
112. Gerald P. Murphy et al., U.S. Serial No. 09/561,502, filed April 28, 2000;
113. Gerald P. Murphy et al., U.S. Serial No. 09/724,630, filed November 28, 2000;
114. Gerald P. Murphy et al., U.S. Serial No. 10/428,360, filed May 1, 2003, U.S. Publication No. 20040024188, published February 5, 2004 (**Exhibit 42**);
115. PCT International Application No. PCT/US02/17298, filed May 30, 2002, International Publication No. WO 02/096460 A1, published December 5, 2002 (**Exhibit 43**);
116. PCT International Application No. PCT/US02/17068, filed May 30, 2002, International Publication No. WO 02/098897 A2, published December 12, 2002 (**Exhibit 44**);
117. U.S. Patent No. 5,935,818, issued August 10, 1999 to Ron S. Israeli et al. (**Exhibit 45**);
118. U.S. Patent No. 6,569,432 B1, issued May 27, 2003 to Ron S. Israeli et al. (**Exhibit 46**);
119. Pending claims in Ron S. Israeli et al., U.S. Serial No. 08/403,803, filed March 17, 1995 (**Exhibit 47**);
120. Pending claims in Ron S. Israeli et al., U.S. Serial No. 08/466,381, filed June 6, 1995 (**Exhibit 48**);
121. Pending claims in Ron S. Israeli et al., U.S. Serial No. 08/470,735, filed June 6, 1995 (**Exhibit 49**);
122. Pending claims in Ron S. Israeli et al., U.S. Serial No. 09/990,595, filed November 21, 2001 (**Exhibit 50**);
123. Pending claims in Ron S. Israeli et al., U.S. Serial No. 09/724,026, filed November 28, 2000 (**Exhibit 51**);
124. Pending claims in Ron S. Israeli et al., U.S. Serial No.

Applicants: Ron S. Israeli et al.
U.S. Serial No.: 10/751,346
Filed: January 2, 2004
Page 12

- 08/481,916, filed June 7, 1995 (**Exhibit 52**);
125. Pending claims in Ron S. Israeli et al., U.S. Serial No. 10/012,169, filed October 24, 2001 (**Exhibit 53**);
126. Pending claims in Ron S. Israeli et al., U.S. Serial No. 10/443,694, filed May 21, 2003, U.S. Publication No. 20040001846, published January 1, 2004 (**Exhibit 54**);
127. Ron S. Israeli et al., U.S. Serial No. 10/614,625, filed July 2, 2003 (**Exhibit 55**);
128. Preliminary Amendment filed July 2, 2003 in connection with U.S. Serial No. 10/614,625 (i.e., reference 127) (**Exhibit 56**);
129. Pending claims in Ron S. Israeli et al., U.S. Serial No. 08/894,583, filed February 23, 1998 (**Exhibit 57**); and
130. PCT International Application No. PCT/US96/02424, filed February 23, 1996, International Publication No. WO 96/26272, published August 29, 1996 (**Exhibit 58**).

The Examiner is respectfully requested to make these references of record in the present application by initialing and dating the PTO 1449 form provided as **Exhibit A**, and returning a copy of the executed form to applicants' representatives with the next Communication concerning this application.

The subject application claims the priority of United States Application Serial No. 08/894,583, filed February 23, 1998, which is a national stage application under 35 U.S.C. 371 of PCT/US96/02424, filed February 23, 1996, which is a continuation-in-part of and claims priority of U.S. Serial Nos. 08/466,381 and 08/470,735, both filed June 6, 1995. Applicants note that the above listed references 1-42 were submitted to the Patent Office in an Information Disclosure Statement filed on July 11, 1997 in connection with U.S. Serial No. 08/466,381. The above listed references 43-50 were submitted to the Patent Office in Supplemental Information Disclosure Statements filed on March 20,

Applicants: Ron S. Israeli et al.
U.S. Serial No.: 10/751,346
Filed: January 2, 2004
Page 13

2000 and January 19, 2001, in connection with U.S. Serial No. 08/466,381. The above listed references 51-61 were submitted to the Patent Office in a Supplemental Information Disclosure Statement filed on June 27, 2001, in connection with U.S. Serial No. 08/470,735. The above listed references 62-64 were cited by the Patent Office in an Office Action issued on May 12, 1998 in connection with U.S. Serial No. 08/466,381. Accordingly, pursuant to 37 C.F.R. §1.98(d), copies of these references are not provided herein since they were previously cited by, or submitted to, the Patent Office in an application relied upon for an earlier filing date under 35 U.S.C. §120.

References 106-110 are applications claiming priority with U.S. Patent No. 6,107,090 to Bander (filed April 9, 1997 under U.S. Serial No. 08/836,682 and issued August 22, 2000). The Bander '090 patent is cited as reference 46 in the present Supplemental Information Disclosure Statement. Copies of references 106-110 are not provided as they are unpublished and unavailable to applicants. However, they are understood to be available to the Examiner for his review and consideration.

References 111-113 are applications claiming priority with U.S. Patent No. 6,150,508 to Murphy et al. (filed March 18, 1998 under Serial No. 09/044,668 and issued November 21, 2000). The Murphy et al. '508 patent is cited as reference 48 in the present Supplemental Information Disclosure Statement. Copies of references 111-113 are not provided as they are unpublished and unavailable to applicants. However, they are understood to be available to the Examiner for his review and consideration.

Applicants note that the above-cited references, 119-125, 127, and 129, are patent applications that are related to the present application and which have neither been issued as patents nor published. Reference 119 is a national stage counterpart of, and

Applicants: Ron S. Israeli et al.
U.S. Serial No.: 10/751,346
Filed: January 2, 2004
Page 14

references 120-123 are continuations of, PCT International Application No. PCT/US93/10624 (reference 4, above), published under International Publication No. WO 94/09820. A copy of International Publication No. WO 94/09820 was submitted to the Patent Office in an Information Disclosure Statement filed on July 11, 1997 in connection with U.S. Serial No. 08/466,381, upon which the subject application relies for an earlier filing date under 35 U.S.C. §120. Thus, as noted above, a copy of reference 4 is not provided herein pursuant to 37 C.F.R. §1.98(d). Further, pursuant to 37 C.F.R. §1.98(c), copies of references 119-123 are also not provided as they are cumulative. However, pursuant to 37 C.F.R. §1.98(a)(2), copies of the claims pending in references 119-123 are provided as **Exhibits 47-51**, respectively.

Reference 124 is a continuation of U.S. Serial No. 08/325,553. A copy of U.S. Serial No. 08/325,553, now U.S. Patent No. 5,538,866 (reference 3, above), was submitted to the Patent Office in an Information Disclosure Statement filed on July 11, 1997 in connection with U.S. Serial No. 08/466,381, upon which the subject application relies for an earlier filing date under 35 U.S.C. §120. Thus, a copy of reference 3 is not provided herein pursuant to 37 C.F.R. §1.98(d). Further, pursuant to 37 C.F.R. §1.98(c), a copy of reference 124 is also not provided as it is cumulative. However, pursuant to 37 C.F.R. §1.98(a)(2), a copy of the claims pending in reference 114 is provided as **Exhibit 52**.

References 125 and 126 are continuations of U.S. Serial No. 08/705,477, now U.S. Patent No. 6,569,432, a copy of which is enclosed as **Exhibit 46**. Pursuant to 37 C.F.R. §1.98(c), copies of references 125 and 126 are not provided as they are cumulative. However, pursuant to 37 C.F.R. §1.98(a)(2), copies of the claims pending in references 125 and 126 are provided as **Exhibits 53 and 54**, respectively.

Applicants: Ron S. Israeli et al.
U.S. Serial No.: 10/751,346
Filed: January 2, 2004
Page 15

Reference 127 (U.S. Serial No. 10/614,625) is a continuation-in-part of U.S. Serial No. 10/433,694, which is a continuation of U.S. Serial No. 08/705,477, now U.S. Patent No. 6,569,432, a copy of which is enclosed as **Exhibit 46**. Applicants attach hereto as **Exhibit 55** a copy of the specification and claims (corresponding to U.S. Serial No. 08/705,477) filed for U.S. Serial No. 10/614,625, together with a July 2, 2003 Preliminary Amendment (copy attached as **Exhibit 56**) which amended the specification and claims of U.S. Serial No. 10/614,625. The amended claims recited in this Preliminary Amendment are currently pending.

Reference 129 is a national stage counterpart of PCT International Application No. PCT/US96/02424, published under International Publication No. WO 96/26272, a copy of which is enclosed as **Exhibit 58**. Pursuant to 37 C.F.R. §1.98(c), a copy of reference 129 is not provided herein as it is cumulative. However, pursuant to 37 C.F.R. §1.98(a)(2), a copy of the claims pending in reference 129 is provided as **Exhibit 57**.

Further to the above, applicants direct the Examiner's attention to the article by Su et al. entitled "Alternatively Spliced Variants of Prostate-specific Membrane Antigen RNA: Ratio of Expression as a Potential Measurement of Progression" (Cancer Research 55: 1441-1443, 1995; reference 60, above), dealing with a splice variant of prostate specific membrane antigen. The first named author of the subject paper, Dr. Sai L. Su, has alleged that he was a co-inventor of claims directed to a splice variant of prostate specific membrane antigen contained in U.S. Patent No. 5,935,818 to Israeli et al. which issued August 10, 1999 and which is assigned to the Assignee of the present case. The subject matter of the claims of U.S. Patent No. 5,935,818 is not, however, the subject matter claimed in the present application. Applicants' representatives are investigating the

Applicants: Ron S. Israeli et al.
U.S. Serial No.: 10/751,346
Filed: January 2, 2004
Page 16

claim raised by Dr. Su.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone either of them at the number provided below.

Pursuant to 37 C.F.R. §1.97(b)(3), no fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

Mark A. Farley

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:
Commissioner for Patents
P.O. Box 1450, Alexandria
VA 22313-1450

Mark A. Farley 3-26-04
John P. White Date
Reg. No. 28,678
Mark A. Farley
Reg. No. 33,170

John P. White
Registration No. 28,678
Mark A. Farley
Registration No. 33,170
Attorneys for Applicant(s)
Cooper & Dunham, LLP
1185 Avenue of the
Americas
New York, New York 10036
(212) 278-0400



Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Atty. Docket No. 41426-F-PCT-US-A/JPW/MAF/AJD		Serial No. 10/751,346										
		Applicant(s) Ron S. Israeli et al.												
		Filing Date January 2, 2004		Art Unit										
U.S. PATENT DOCUMENTS														
Examiner Initials	Exh No	Document Number							Date	Name	Class	Subclass	Filing Date If Appropriate	
		4	5	5	4	1	0	1	11/19/85	Hopp				
		5	1	5	3	1	1	8	10/06/92	Wright et al.				
		5	1	6	2	5	0	4	11/10/92	Horoszewicz				
		5	5	3	8	8	6	6	07/23/96	Israeli et al.				
	1	5	6	7	2	5	9	2	09/30/97	Jackson et al.				
	2	5	7	9	5	8	7	7	08/18/98	Jackson et al.				
	3	5	8	0	4	6	0	2	09/08/98	Slusher et al.				
FOREIGN PATENT DOCUMENTS														
		Document Number							Date	Country	Class	Subclass	Translation	
		9	4	0	9	8	2	0	05/11/94	PCT			Yes	No
		9	7	3	5	6	1	6	10/02/97	PCT				
		9	9	4	7	5	5	4	09/23/99	PCT				
	43	02	0	9	6	4	6	0	12/05/02	PCT				
	44	02	0	9	8	8	9	7	12/12/02	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
		Abdel-Nabi, H., Wright, G.L., Gulfo, J.V., Petrylak, D.P., Neal, C.E. et al. (1992) Monoclonal Antibodies and Radioimmunoconjugates in the Diagnosis and Treatment of Prostate Cancer, <i>Semin. Urol.</i> 10: 45-54;												
		Axelrod, H.R. et al. (1992) Preclinical results and human immunohistochemical studies with ⁹⁰ Y-CYT-356. A new prostate cancer therapeutic agent, <i>Abstract 596. AUA 87th Annual Meeting</i> , May 10-14, 1992, Washington, D.C.;												
		Bowie, J.U., Reidhaar-Olson, J.F., Lim, W.A. and Sauer, R.T. (1990) Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions, <i>Science</i> 147: 1306-1310;												
		Carter, B.H. and Coffey, D.S. (1990) The Prostate: An Increasing Medical Problem, <i>The Prostate</i> 16: 39-48;												
		Chang, C.S., Kokontis, J. and Liao, S.T. (1988) Structural Analysis of Complementary DNA and Amino Acid Sequences of Human and Rat Androgen Receptors, <i>Proc. Natl. Acad. Sci. USA</i> 85: 7211-7215;												
EXAMINER										DATE CONSIDERED				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office										Atty. Docket No. 41426-F-PCT-US-A/JPW/MAF/AJD		Serial No. 10/751,346			
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)										Applicant(s) Ron S. Israeli et al.					
										Filing Date January 2, 2004		Art Unit			
U.S. PATENT DOCUMENTS															
Examiner Initials	Exh No	Document Number							Date	Name	Class	Subclass	Filing Date If Appropriate		
		5	8	5	2	1	6	7	12/22/98	Kay et al.					
	4	5	8	6	3	5	3	6	01/26/99	Jackson et al.					
	5	5	8	8	0	1	1	2	03/09/99	Jackson et al.					
	6	5	9	0	2	8	1	7	05/11/99	Jackson et al.					
		5	9	3	9	2	5	8	08/17/99	Croce et al.					
	7	5	9	6	2	5	2	1	10/05/99	Jackson et al.					
	8	5	9	6	8	9	1	5	10/19/99	Jackson et al.					
	9	5	9	8	1	2	0	9	11/09/99	Slusher et al.					
FOREIGN PATENT DOCUMENTS															
		Document Number							Date	Country	Class	Subclass	Translation		
														Yes	No
	58	9	6	2	6	2	7	2	08/29/96	PCT					
		0	1	7	3	9	5	1	12/03/86	EPO					
		0	1	7	3	9	5	1	12/03/86	EPO				X	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)															
		Corr, J.G. et al. (1994) Prostate Specific Membrane Antigen (PSM) Expression in Orthotopically Implanted Human Prostate Cancer Cells in Nude Mice Slows Tumor Growth and Metastatic Potential, <i>J. Urol.</i> 151: 492A;													
		Culver, K.W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E.H. and Blaese, R.M. (1992) In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors, <i>Science</i> 256: 1150-1552;													
		Decensi, A., Guarneri, D., Paoletti, M.C., Lalanne, J.M., Merlo, F. and Boccardo, F. (1991) Phase II Study of the Pure Non-steroidal Antiandrogen Nilutamide in Prostatic Cancer, <i>Eur. J. Cancer</i> 27: 1100-1104;													
		Faber, P.W., van Rooij, H.C., van der Korput, H.A., Baarends, W.M., Brinkmann, A.O., Grootegoed, J.A. and Trapman, J. (1991) Characterization of the Human Androgen Transcription Unit, <i>J. Biol. Chem.</i> 266: 10743-10749;													
		Feng, Q. et al. (1991) Purification and Biochemical Characterization of the 7E11-C5 Prostate Carcinoma-Associated Antigen, <i>Proc. Am. Assoc. Cancer Res.</i> 32: 239;													
EXAMINER									DATE CONSIDERED						
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.															

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 41426-F-PCT-US- A/JPW/MAF/AJD		Serial No. 10/751,346						
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant(s) Ron S. Israeli et al.								
					Filing Date January 2, 2004		Art Unit						
U.S. PATENT DOCUMENTS													
Examiner Initials	Exh No.	Document Number							Date	Name	Class	Subclass	Filing Date If Appropriate
	10	6	0	1	1	0	2	1	01/04/00	Slusher et al.			
	11	6	0	1	7	9	0	3	01/25/00	Slusher et al.			
	12	6	0	2	5	3	4	4	02/15/00	Jackson et al.			
	13	6	0	2	5	3	4	5	02/15/00	Jackson et al.			
	14	6	0	4	6	1	8	0	04/04/00	Jackson et al.			
	15	6	0	5	4	4	4	4	04/25/00	Jackson et al.			
		6	1	0	7	0	9	0	08/22/00	Bander			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
		Fey, M.F., Kulozik, A.E., Hansen-Hagge, T.E. and Tobler, A. (1991) The Polymerase Chain Reaction: A New Tool for the Detection of Minimal Residual Disease in Haematological Malignancies, <i>Eur. J. Cancer</i> 27: 89-94;											
		Gately, M.K., Wolitzky, A.G., Quinn, P.M. and Chizzonite, R. (1992) "Regulation of Human Cytolytic Lymphocyte Responses by Interleukin-12", <i>Cell. Immunol.</i> 143: 127-142;											
		Henttu, P. and Vihko, P. (1989) cDNA Coding for the Entire Human Prostate Specific Antigen Shows High Homologies to the Human Tissue Kallikrein Genes, <i>Biochem. Biophys. Res. Commun.</i> 160: 903-910;											
		Horoszewicz, J.S., Kawinski, E. and Murphy, G.P. (1987) Monoclonal Antibodies to a New Antigen Marker in Epithelial Prostatic Cells and Serum of Prostatic Cancer Patients, <i>AntiCancer Res.</i> 7: 927-936;											
		Huber, B.E., Richards, C.A. and Krenitsky, T.A. (1991) Retroviral-mediated Gene Therapy for the Treatment of Hepatocellular Carcinoma: An Innovative Approach for Cancer Therapy, <i>Proc. Natl. Acad. Sci. USA</i> 88:8039-8043;											
		Israeli, R.S. et al., (1992) Purification and Molecular Cloning of a New Prostate-Specific Antigen, <i>Cancer Res.</i> 52: 356;											
		Israeli, R.S., Powell, C.T., Fair, W.R. and Heston, W.D. (1993) Molecular Cloning of a Complementary DNA Encoding a Prostate-specific Membrane Antigen, <i>Cancer Res.</i> 53: 227-230;											
		Israeli, R.S. et al. (1993) Molecular Cloning and Characterization of a Prostate-Specific Membrane Antigen, <i>J. Urol.</i> 149: 471A;											
		Israeli, R.S. et al. (1993) Characterization of the Prostate-Specific Membrane Antigen (PSM), <i>Proc. Am. Assoc. Cancer Res.</i> 34: 255;											
EXAMINER									DATE CONSIDERED				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 41426-F-PCT-US- A/JPW/MAF/AJD		Serial No. 10/751,346							
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicant(s) Ron S. Israeli et al.									
				Filing Date January 2, 2004		Art Unit							
U.S. PATENT DOCUMENTS													
Examiner Initials	Exh No	Document Number							Date	Name	Class	Subclass	Filing Date If Appropriate
	16	6	1	2	1	2	5	2	09/19/00	Jackson et al.			
		6	1	3	6	3	1	1	10/24/00	Bander			
	17	6	2	7	1	2	4	5	08/07/01	Jackson et al.			
	18	6	2	8	8	0	4	6	09/11/01	Jackson et al.			
	19	6	3	4	8	4	6	4	02/19/02	Jackson et al.			
	20	6	3	7	2	7	2	6	04/16/02	Slusher et al.			
	21	6	3	8	4	0	2	2	05/07/02	Jackson et al.			
	22	6	3	9	5	7	1	8	05/28/02	Slusher et al.			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
		Israeli, R.S., Powell, C.T., Corr, J.G., Fair, W.R. and Heston, W.D. (1994) Expression of the Prostate Specific Membrane Antigen, <i>Cancer Res.</i> 54: 1807-1811;											
		Israeli, R.S., Miller, W.H. Jr., Su, S.L., Powell, C.T., Fair, W.R. et al. (1994) Sensitive Nested Reverse Transcription Polymerase Chain Reaction Detection of Circulating Prostatic Tumor Cells: Comparison of Prostate-specific Membrane Antigen and Prostate-specific Antigen-based Assays, <i>Cancer Research</i> 54: 6306-6310;											
		Israeli, R.S. et al. (1994) Localization of the Prostate Specific Membrane Antigen (PSM) to the Putative Metastasis-Suppressor Region on Human Chromosome 11, <i>J. Urol.</i> 151: 252A;											
		Israeli, R.S. et al., (1994) Sensitive Detection of Prostatic Hematogenous Micro-Metastases Using Prostate Specific Antigen (PSA) And Prostate Specific Membrane Antigen (PSM) Derived Primers in the Polymerase Chain Reaction (PCR), <i>J. Urol.</i> 151: 373A;											
		Israeli, R.S. et al. (1994) Localization of the Prostate Specific Membrane Antigen (PSM) to the Putative Metastasis-Suppressor Region on Human Chromosome 11, <i>Proc. Am. Assoc. Cancer Res.</i> 35: 271;											
		Keer, H.N., Kozlowski, J.M., Tsai, Y.C., Lee, C., McEwan, R.N. and Grayhack, J.T. (1990) Elevated Transferrin Receptor Content in Human Prostate Cancer Cell Lines Assessed In Vitro and In Vivo, <i>J. Urol.</i> 143: 381-385;											
		Kumar, V., Urban, J.L., Horvath, S.J. and Hood, L. (1990) Amino Acid Variations at a Single Residue in an Autoimmune Peptide Profoundly Affect Its Properties: T-Cell Activation, Major Histocompatibility Complex Binding, and Ability to Block Experimental Allergic Encephalomyelitis, <i>Proc. Natl. Acad. Sci. USA</i> 87: 1337-1341;											
EXAMINER									DATE CONSIDERED				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 41426-F-PCT-US-A/JPW/MAF/AJD		Serial No. 10/751,346						
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant(s) Ron S. Israeli et al.								
					Filing Date January 2, 2004		Art Unit						
U.S. PATENT DOCUMENTS													
Examiner Initials	Exh No	Document Number							Date	Name	Class	Subclass	Filing Date If Appropriate
	23	6	4	1	3	9	4	8	07/02/02	Slusher et al.			
	24	6	4	5	2	0	4	4	09/17/02	Jackson et al.			
	25	6	4	5	8	7	7	5	10/01/02	Jackson et al.			
	26	6	4	7	9	4	7	1	11/12/02	Jackson et al.			
	27	6	5	8	6	6	2	3	07/01/03	Tsukamoto et al.			
	28	2 0 0 2 / 0 0 1 3 2 9 5							01/31/02	Slusher et al.			05/30/01
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
		Lazar, E., Watanabe, S., Dalton, S. and Sporn, M.B. (1988) Transforming Growth Factor α : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities, <i>Mol. Cell Biol.</i> 8: 1247-1252;											
		Lopes, A. D. et al. (1993) Immunohistochemical and Pharmacokinetic Characterization of the Site-specific Immunoconjugate CYT-356 Derived from Antiprostate Monoclonal Antibody, <i>Cancer Res.</i> 50: 6423-6429;											
		Lubahn, D.B., Brown, T.R., Simental, J.A., Higgs, H.N., Migeon, C.J., Wilson, E.M. and French, F.S. (1989) Sequence of the Intron/exon Junctions of the Coding Region of the Human Androgen Receptor Gene and Identification of a Point Mutation in a family with Complete Androgen Insensitivity, <i>Proc. Natl. Acad. Sci. USA</i> 86: 9534-9538;											
		Lundwall, A, and Lilja, H. (1987) Molecular Cloning of Human Prostate Specific Antigen cDNA, <i>FEBS Lettr.</i> 214: 317-322;											
		Mukhopadhyay, T., Tainsky, M., Cavender, A.C. and Roth, J.A. (1991) Specific Inhibition of K-ras Expression and Tumorigenicity of Lung Cancer Cells by Antisense RNA ¹ , <i>Cancer Res.</i> 51: 1744-1748;											
		Paul, W.E. (1989) <i>Fundamental Immunology</i> , Raven Press, pp. 628-629, 647-651;											
		Riegman, P.H.J. et al. (1989) The Prostate-Specific Antigen Gene and the Human Glandular Kallikrein-1 Gene are Tandemly Located on Chromosome 19, <i>FEBS Lettr.</i> 247: 123-126;											
		Rose, N.R. et al. (1986) <i>Manual of Clinical Laboratory Immunology</i> , American Society for Microbiology, 89-109;											
		Rossi, M. C. and Zetter, B.R. (1992) Selective Stimulation of Prostatic Carcinoma Cell Proliferation by Transferrin, <i>Proc. Natl. Acad. Sci. USA</i> 89: 6197-6201;											
EXAMINER									DATE CONSIDERED				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 41426-F-PCT-US-A/JPW/MAF/AJD		Serial No. 10/751,346	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant(s) Ron S. Israeli et al.			
					Filing Date January 2, 2004		Art Unit	
U.S. PATENT DOCUMENTS								
Examiner Initials	Exh No	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate	
	29	2 0 0 2 / 0 0 1 9 4 3 0	02/14/02	Jackson et al.			05/30/01	
	30	2 0 0 2 / 0 0 4 4 4 5 9	11/22/01	Jackson et al.			06/15/01	
	31	2 0 0 3 / 0 1 0 5 0 8 8	06/05/03	Tsukamoto et al.			01/17/02	
	32	2 0 0 2 / 0 1 5 1 5 0 3	10/17/02	Slusher et al.			01/28/02	
	33	2 0 0 3 / 0 0 6 4 9 1 2	04/13/03	Slusher et al.			04/11/02	
	34	2 0 0 3 / 0 0 8 3 3 7 4	05/01/03	Jackson et al.			06/10/02	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
		Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) <i>Molecular Cloning, A Laboratory Manual</i> , Cold Spring Harbor Laboratory Press, 16.1-16.81;						
		Schneider, C., Owen, M.J., Banville, D. and Williams, J.G. (1984) Primary Structure of Human Transferrin Receptor Deduced from the mRNA sequence, <i>Nature</i> 311: 675-678;						
		Sharief, F.S., Lee, H., Leuderman, M.M., Lundwall, A., Deaven, L.L., Lee, C.L. and Li, S.S. (1989) Human prostatic acid phosphatase: cDNA cloning, gene mapping and protein sequence homology with lysosomal acid phosphatase. <i>Biochem. Biophys. Res. Commun.</i> 160: 79-86;						
		Solin, T., Kontturi, M., Pohlmann, R. and Vihko, P. (1990) Gene Expression and Prostate Specificity of Human Prostatic Acid Phosphatase (PAP): Evaluation By RNA Blot Analyses, <i>Biochem. Biophys. Acta</i> 1048: 72-77;						
		Stites, D.P. et al. (1991) <i>Basic and Clinical Immunology</i> , Appleton & Lange, 229-251;						
		Su, S.L., et al. (1994) Sensitive Detection of Prostatic Hematogenous Micrometastases Using Prostate Specific Antigen (PSA) and Prostate Specific Membrane Antigen (PSM) Derived Parameters in the Polymerase Chain Reaction, <i>Proc. Am. Assoc. Cancer Res.</i> 35: 271;						
		Su, S.L., Huang, I.P., Fair, W.R., Powell, C.T. and Heston, W.D. (1995) <i>Cancer Res.</i> , 55: 1441-1443;						
		Tortora, G.J. et al. (1989) <i>Microbiology, An Introduction</i> , Benjamin/Cummings Publishing Co., 423-426, 471;						
		Troyer, John K. (1994) Biochemical Characterization and Mapping of the 7E11-C5.3 Epitope of the Prostate Specific Membrane Antigen (PSMA), <i>Basic and Clinical Aspects of Prostate Cancer: Abstract C38</i> ;						
EXAMINER				DATE CONSIDERED				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 41426-F-PCT-US- A/JPW/MAF/AJD		Serial No. 10/751,346	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant(s) Ron S. Israeli et al.			
					Filing Date January 2, 2004		Art Unit	
U.S. PATENT DOCUMENTS								
Examiner Initials	Exh No	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate	
	35	2 0 0 3 / 0 0 1 7 9 6 5	01/23/03	Slusher et al.			08/01/02	
	36	2 0 0 3 / 0 2 1 6 4 6 8	11/20/03	Tsakamoto et al.			05/08/03	
	37	5 7 7 3 2 9 2	06/30/98	Bander				
	38	6 6 4 9 1 6 3	11/18/03	Bander				
	39	2 0 0 2 / 0 0 1 5 7 0 4	02/07/02	Bander			08/13/01	
	40	2 0 0 3 / 0 0 3 1 6 7 3	02/13/03	Bander			08/13/01	
	41	2 0 0 3 / 0 0 0 7 9 7 4	01/09/03	Nanus et al.			05/30/02	
		0 9 3 5 7 7 0 4		Bander			07/20/99	
		0 9 3 5 7 7 0 7		Bander			07/20/99	
		0 9 3 5 7 7 0 8		Bander			07/20/99	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
		Vihko, P., Virkkunen, P., Henttu, P., Roiko, K., Solin, T. and Huhtala, M.L. (1988) Molecular Cloning and Sequence Analysis of cDNA Encoding Human Prostatic Acid Phosphatase, <i>FEBS Lettr.</i> 236: 275-281;						
		Vile, R.G. and Hart, I.R. (1993) In Vitro and In Vivo Targeting of Gene Expression to Melanoma Cells, <i>Cancer Res.</i> 53: 962-967;						
		Waibel, R. et al. (1990) Therapy of Small Cell Lung Cancer Xenografts in a Nude Mouse model: Evaluation of Radioimmunotherapy and Immunotoxin Therapy, <i>Antibody Immunoconjugates and Radiopharmaceuticals</i> 34: 54;						
		Watt, K.W.K. et al. (1986) Human Prostate-Specific Antigen: Structural and Functional Similarity with Serine Proteases, <i>Proc. Natl. Acad. Sci. USA</i> 83: 3166-3170;						
		Wright, Jr., G.L, Feng, Q., Beckett, M.L., Lopes, D. and Gilman, S.C. (1990) Characterization of a new prostate carcinoma-associated marker: 7E11-C5. <i>Antibody, Immunoconjugates and Radiopharmaceuticals</i> 3: 89 (Abstract 193); and						
		Young, R.A. and Davis, R.W. (1983) Efficient Isolation of Genes by Using Antibody Probes, <i>Proc. Natl. Acad. Sci. USA</i> 80: 1194-1198.						
EXAMINER				DATE CONSIDERED				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Atty. Docket No. 41426-F-PCT-US-A/JPW/MAF/AJD Applicant(s) Ron S. Israeli et al. Filing Date January 2, 2004		Serial No. 10/751,346 Art Unit										
U.S. PATENT DOCUMENTS														
Examiner Initials	Exh No	Document Number							Date	Name	Class	Subclass	Filing Date If Appropriate	
		0	9	3	5	7	7	0	9		Bander			07/20/99
		0	9	3	5	7	7	1	0		Bander			07/20/99
		0	9	5	6	1	4	6	2		Murphy et al			04/28/00
		0	9	5	6	1	5	0	2		Murphy et al			04/28/00
		0	9	7	2	4	6	3	0		Murphy et al			11/28/00
	42	2 0 0 4 / 0 0 2 4 1 8 8							02/05/04	Murphy et al.				05/01/03
	45	5	9	3	5	8	1	8		08/10/99	Israeli et al.			
	46	6	5	6	9	4	3	2		05/27/03	Israeli et al.			
	47	0	8	4	0	3	8	0	3		Israeli et al.			03/17/95
	48	0	8	4	6	6	3	8	1		Israeli et al.			06/06/95
	49	0	8	4	7	0	7	3	5		Israeli et al.			06/06/95
	50	0	9	9	9	0	5	9	5		Israeli et al.			11/21/01
	51	0	9	7	2	4	0	2	6		Israeli et al.			11/28/00
	52	0	8	4	8	1	9	1	6		Israeli et al.			06/07/95
	53	1	0	0	1	2	1	6	9		Israeli et al.			10/24/01
	54	2 0 0 4 / 0 0 0 1 8 4 6							01/01/04	Israeli et al.				05/21/03
	55	1	0	6	1	4	6	2	5		Israeli et al.			07/02/03
	56	Preliminary Amendment re Exhibit 55								Israeli et al.				07/02/03
	57	0	8	8	9	4	5	8	3		Israeli et al.			02/13/98
EXAMINER										DATE CONSIDERED				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														